URGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Urogen Pharma Ltd (URGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong growth potential driven by its innovative product Zusduri, favorable analyst ratings, and significant hedge fund interest. While financials show a net income decline, the revenue growth and high gross margin indicate the company is scaling effectively. The technical indicators and options sentiment are neutral to slightly positive, and there are no major negative catalysts at this time.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 75.072, which is in the neutral zone but approaching overbought levels. Moving averages are converging, suggesting consolidation. The stock is trading near its resistance level of 21.046 in pre-market, showing potential for a breakout.
Jefferies analyst initiated a Buy rating with a $40 price target, citing strong Phase 3 data for Zusduri and favorable risk/reward.
Hedge funds are significantly increasing their positions, with a 194.83% increase in buying activity last quarter.
Revenue growth of 54.03% YoY in Q4 2025 and a gross margin of 91.31%.
Net income dropped by 29.72% YoY, and EPS declined by 16.92% YoY in Q4
No recent news or significant insider trading trends.
Stock trend analysis suggests a 60% chance of minor declines in the short term (-1.8% in the next day, -0.58% in the next week).
In Q4 2025, revenue increased by 54.03% YoY to $37.84 million, demonstrating strong growth. However, net income dropped by 29.72% YoY to -$26.36 million, and EPS fell by 16.92% YoY to -$0.54. Gross margin improved slightly to 91.31%, indicating operational efficiency.
Jefferies initiated coverage with a Buy rating and a $40 price target, highlighting strong Phase 3 data for Zusduri and favorable risk/reward. Analysts expect accelerated uptake as payer frictions ease.
